Research Corporation Technologies Acquires Translational Drug Development (TD2)

Treadwell Therapeutics Acquires TCRyption Inc.

October 15, 2021

Biotechnology

Treadwell Therapeutics announced it has acquired TCRyption Inc., a TIO Bioventures–backed developer of a novel TCR-identification platform for T cell therapies, in a stock-swap transaction. The acquisition brings the TCRypt platform and a bank of TCR candidates into Treadwell's pre-clinical oncology pipeline to expand its cell-therapy capabilities, with initial TCR programs expected to enter the clinic in early 2023.

BroadOak Capital Partners and RCT Invest in Biolog, Inc.

May 12, 2022

Biotechnology

BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.

TransTech Group Acquires Cryogenic Technology Resources (CTR)

September 26, 2024

Industrial Services

TransTech Group, a portfolio company of Bridge Industries, has acquired Cryogenic Technology Resources (CTR) to expand its cryogenic systems, fabrication, service and automation capabilities. The deal strengthens TransTech’s end-to-end offering for industrial gas, air separation, and related end markets while expanding geographic reach and service capacity.

Velocity Clinical Research Acquires TrierHealth

February 22, 2022

Healthcare Services

Durham-based Velocity Clinical Research acquired digital clinical trials platform TrierHealth, bringing its founder Raghu Punnamraju into Velocity as Chief Technology Officer. The acquisition adds Hyderabad-based R&D talent and patient-engagement technology to accelerate Velocity’s move toward decentralized and hybrid clinical trials.

CD&R, Merck GHI and McKesson Ventures Recapitalize M2GEN

March 17, 2021

Healthcare Services

Clayton, Dubilier & Rice (CD&R) led a recapitalization of oncology data and informatics company M2GEN, with strategic investments from Merck Global Health Innovation Fund and McKesson Ventures. The transaction — which closed with terms undisclosed — positions CD&R as the largest shareholder and will fund growth of M2GEN's linked clinical and genomic data assets and expanded technology and informatics capabilities.

Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

March 6, 2023

Healthcare Services

Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.